Parecoxib
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
- Parecoxib
- Pharmacist Assessment Report
- Parecoxib: From Perioperative Pain (Indication Not Recorded) to Migraine Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Parecoxib: From Perioperative Pain (Indication Not Recorded) to Migraine Disorder
One-Sentence Summary
Parecoxib is an injectable prodrug of valdecoxib, a selective COX-2 inhibitor. The approved indication text for the Indian licences was not available in the data compiled for this report. The TxGNN model predicts it may be effective for migraine disorder, with 0 registered clinical trials and 1 clinical publication (a small pilot-type comparison against triptans) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Indian licence data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9955 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data |
| Number of Listed Products | 5 (valid: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled drug record. Based on known pharmacology, parecoxib is a prodrug of valdecoxib, a selective COX-2 inhibitor with anti-inflammatory and analgesic properties.
COX-2-driven prostaglandin (PGE2) synthesis contributes to neurogenic inflammation, trigeminal sensitization and CGRP release in migraine. Inhibiting COX-2 is therefore mechanistically plausible for treating an acute attack. Preclinical work is consistent with this: parecoxib affected plasma protein extravasation and c-fos expression in a rat model of trigeminovascular activation, and IL-1β was shown to stimulate COX-2-dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells.
The TxGNN score is very high, but it is a model prediction only. The single clinical paper is a pilot comparison of intravenous parecoxib 40 mg, oral rizatriptan and subcutaneous sumatriptan. Its design and size cannot be verified from the available information, and it may be small or non-randomized. The data do not support an evidence level above L3.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21996647 | 2011 | Clinical (pilot) study | Clinical Neuropharmacology | Compared intravenous parecoxib 40 mg with rizatriptan and sumatriptan in acute migraine attacks; design not verifiable |
| 16492237 | 2006 | Preclinical (rat) | Headache | Parecoxib effects on meningeal plasma protein extravasation and c-fos expression in a trigeminovascular model |
| 21394197 | 2011 | Preclinical (in vitro) | PLoS One | IL-1β stimulates COX-2-dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells |
The two preclinical papers were compiled under related migraine-susceptibility predictions but support the same mechanism.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 181565 | Praxis 40mg Injection (Lupin Ltd) | Vial of 1 injection | Not available |
| 239256 | Valdin P 40mg Injection (Orchid Chemicals & Pharmaceuticals Ltd) | Vial of 1 injection | Not available |
| 238913 | Valdixx 40mg Injection (Cipla Ltd) | Vial of 2 ml injection | Not available |
| 239567 | Valz 40mg Injection (Torque Pharmaceuticals Pvt Ltd) | Vial of 2 ml injection | Not available |
| 209511 | Superin 40mg Injection (Neon Laboratories Ltd) | Vial of 1 injection | Not available |
All five licences are valid single-ingredient injectable products.
Safety Considerations
Please refer to the package insert for safety information.
Mechanistically, selective COX-2 inhibitors carry recognised cardiovascular safety concerns, which should be weighed in any new use.
Conclusion and Next Steps
Decision: Hold
Rationale: The only clinical support is a single pilot-type study of unverified design, with no registered trials. The remaining evidence is preclinical, and the high TxGNN score is a prediction only. The other predicted indications (migraine with brainstem aura, migraine susceptibility, pulmonary hypertension) have weaker evidence, and for pulmonary hypertension potential harm cannot be excluded. Migraine-related predictions should be consolidated under migraine disorder.
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indications from the Indian licences
- Detailed mechanism of action data
- Full review of the 2011 pilot study’s design, sample size and outcomes
- Randomized controlled trial evidence for parecoxib in acute migraine
- A cardiovascular risk assessment and a safety plan for repeated or non-surgical use
- Confirmation of the injectable route’s practicality for migraine
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.